Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis
about
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung diseaseTopical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung diseaseTopical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung diseaseTopical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung diseaseSequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifsTaking stock of gene therapy for cystic fibrosis"Bronchial artery delivery of viral vectors for gene delivery in cystic fibrosis; superior to airway delivery?".Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung diseaseNew and emerging targeted therapies for cystic fibrosisPathophysiology of gene-targeted mouse models for cystic fibrosisLaser fluorescence bronchoscopy for detection of fluorescent reporter genes in airway epithelia.Status of gene therapy for cystic fibrosis lung diseaseCoxsackievirus and adenovirus receptor amino-terminal immunoglobulin V-related domain binds adenovirus type 2 and fiber knob from adenovirus type 12Engineering viral vectors to subvert the airway defense response.Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome.Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins.Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organsRegulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3.A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epitheliaAirway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth.Current status of gene therapy for cystic fibrosis pulmonary disease.Lysophosphatidylcholine as an adjuvant for lentiviral vector mediated gene transfer to airway epithelium: effect of acyl chain length.Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis.Recombinant adenoviral vectors can induce expression of p73 via the E4-orf6/7 proteinCurrent status of gene therapy for inherited lung diseasesImmunological hurdles to lung gene therapy.Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy.Cystic Fibrosis Gene Therapy in the UK and Elsewhere.Adenovirus-mediated gene transfer to ciliated airway epithelia requires prolonged incubation time.Advances in cell and gene-based therapies for cystic fibrosis lung diseaseProtective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.Gene therapy for the treatment of cystic fibrosis.Lentivirus vector can be readministered to nasal epithelia without blocking immune responsesActivation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cellsInhibition of bovine endothelial cell activation in vitro by regulated expression of a transdominant inhibitor of NF-kappa B.Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection
P2860
Q24198270-6D858E5C-4C3E-4C9C-A820-8770376A21EAQ24202357-74AE9F84-9143-42F0-8F35-6BC90F1A3661Q24245035-137064DB-302F-4FCB-94AA-01B8BCF0DDACQ24245040-6D290E3D-6E96-4BA0-9D5A-6569E4A5B629Q24644853-455E6281-B031-4F91-98A1-518C0BC32D33Q24791317-C7E5E524-2E1E-4486-90C6-6EF96DB663EBQ24807085-CD3104CE-31BF-48D1-8693-B4D3580384D1Q26471459-03D34040-3B78-4593-B5DE-D96F817CED01Q26749278-06830313-1355-4A16-886E-724D13CEC3DEQ28295602-4BE4FB6B-CE33-4B64-A1B9-F9D8A46559BEQ33185135-5F5CC36B-C501-423C-9D51-58BFE2C85BB8Q33533855-77BF1F4B-F6B8-4C04-89A7-DAA2CF097289Q33641414-26BC45D0-FE0F-48F7-91A6-4647AE9A1064Q33643006-7E2D4698-DD37-48AF-9B1E-AD6C9FFCD6E6Q33652551-5D691C04-37AD-4FF2-82FD-543E904CF7F8Q33782487-57707F4E-0096-481A-A62F-7CC94CA1C732Q33785925-FAAE42D5-2DAD-4710-A6F6-4B6848BCB2C8Q33817535-2BEB1F6B-3E45-4404-95B2-E55A934A12EBQ33819873-9DB9E28C-9262-4046-A4AC-5929FC4DCAACQ33820928-05A7484B-12A3-46F0-AA69-D42594C548E9Q33901983-7BC06D3A-FE04-4701-85E6-5DE03E9E5E0FQ33911986-AAAC5231-E55F-4DCA-99C8-473249ABF22EQ33929671-C668B703-F885-4AB0-83D9-5B36C06F0D14Q33975113-CC9076BB-622C-42A3-BE33-8DE4C3CAF18CQ34000604-5B28C954-70E2-4CBC-93E2-CF2563E52535Q34348149-E5ADCBB6-4D24-4B76-96F8-8C4E912369D1Q34648372-EA7B179D-24D0-4A3F-9E64-3D4718AAB567Q35043830-13413FF5-5AE3-4C4E-975B-B7C40497455FQ35091006-1E7B7631-C526-42A4-8137-B36C65BF9150Q35200182-54B0147F-85E2-4CE5-80BF-51B003D3B438Q35641704-AF43D9A4-1E96-4849-AFDA-764ED8F2C6B8Q35870623-DAFEF20A-8C17-46C7-98E1-B40FD215A448Q36014033-92AB13BA-C3FF-4A09-AD92-59AB02111100Q36143517-389ECD24-B01B-4573-84D8-6AD74F39B298Q36891541-0B356660-37FF-48D6-BCD5-35F273AED85DQ36925241-2D4DBA50-268C-4692-9B38-00DA2FA8D09AQ36949698-0D6D6EE9-72EA-432C-AAB0-39C5FC36116DQ36979919-21796C15-DE47-4893-B85D-2A871C9070B4Q37363570-5138E2F3-69E1-475C-848C-D7666405AC38Q37371791-875CA115-9CEE-4BA7-B03B-FBA88E0C753E
P2860
Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Repeat administration of an ad ...... patients with cystic fibrosis
@en
Repeat administration of an ad ...... patients with cystic fibrosis.
@nl
type
label
Repeat administration of an ad ...... patients with cystic fibrosis
@en
Repeat administration of an ad ...... patients with cystic fibrosis.
@nl
prefLabel
Repeat administration of an ad ...... patients with cystic fibrosis
@en
Repeat administration of an ad ...... patients with cystic fibrosis.
@nl
P2093
P2860
P921
P356
P1476
Repeat administration of an ad ...... patients with cystic fibrosis
@en
P2093
Balfour RP
Launspach J
Moscicki RA
Richards SM
Standaert TA
P2860
P304
P356
10.1172/JCI118573
P407
P577
1996-03-01T00:00:00Z